The effects of oral magnesium supplementation on glycaemic control in patients with type 2 diabetes: a systematic review and dose-response meta-analysis of controlled clinical trials
Asbaghi O, Moradi S, Kashkooli S, Zobeiri M, Nezamoleslami S, Hojjati Kermani MA, Lazaridi AV, Miraghajani M
The British journal of nutrition · 18 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Meta-analysis (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2022-01-20 · Br J Nutr · vol. 128 · issue 12 · pp. 2363–2372
- Publisher
- Cambridge University Press
- Cited
- 30 citations · more than 70% of similar papers · 1.1× the field average
- References
- 65 works
- Access
- Paywalled
- Research areas
- Magnesium in Health and Disease · Parathyroid Disorders and Treatments · Microbial Metabolites in Food Biotechnology
- Keywords
- Clinical trial, Diabetes mellitus, Sample size determination, Meta-analysis, Analysis of variance, Randomized controlled trial, Fasting blood sugar, Type 2 Diabetes Mellitus
- MeSH
- humans, diabetes mellitus, type 2, magnesium, blood glucose, dietary supplements, glycemic control, glycated hemoglobin
8 authors
From IR, GB
- Omid AsbaghiShahid Beheshti University of Medical Sciences
- Sajjad Moradi · correspondingKermanshah University of Medical Sciences
- Sara KashkooliShahid Beheshti University of Medical Sciences
- Mehdi ZobeiriKermanshah University of Medical Sciences
- Shokufeh NezamoleslamiIsfahan University of Medical Sciences
- Mohammad Ali Hojjati KermaniShahid Beheshti University of Medical Sciences
Abstract
The current systematic review and meta-analysis were conducted to evaluate the effects of oral Mg supplementation on glycaemic control in type 2 diabetes mellitus (T2DM) patients. Related articles were found by searching the PubMed, SCOPUS, Embase and Web of Science databases (from inception to 30 February 2020). A one-stage robust error meta-regression model based on inverse variance weighted least squares regression and cluster robust error variances was used for the dose-response analysis between Mg supplementation and duration of intervention and glycaemic control factors. Eighteen eligible randomised clinical trials were included in our final analysis. The dose-response testing indicated that the estimated mean difference in HbA1c at 500 mg/d was -0·73 % (95 % CI: -1·25, -0·22) suggesting modest improvement in HbA1c with strong evidence (P value: 0·004). And in fasting blood sugar (FBS) at 360 mg/d was -7·11 mg/dl (95 % CI: -14·03, -0·19) suggesting minimal amelioration in FBS with weak evidence (P value: 0·092) against the model hypothesis at this sample size. The estimated mean difference in FBS and HbA1c at 24 weeks was -15·58 mg/dl (95 % CI: -24·67, -6·49) and -0·48 (95 % CI: -0·77, -0·19), respectively, suggesting modest improvement in FBS (P value: 0·034) and HbA1c (P value: 0·001) with strong evidence against the model hypothesis at this sample size. Oral Mg supplementation could have an effect on glycaemic control in T2DM patients. However, the clinical trials so far are not sufficient to make guidelines for clinical practice.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.